Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Oncology Indications Should Continue Denosumab’s Upward Trajectory

Executive Summary

Already on an upward trajectory in oncology uses, Amgen’s denosumab, known as Prolia and Xgeva, got a bit of a boost with FDA approval of two new indications for treatment-induced bone loss in prostate and breast cancer – though neither is expected to add much to the bottom line.

You may also be interested in...



Phase III Results For Bayer/Algeta's Alpharadin Hint Of Labeling Down The Line

In what's become a crowded field of drugs for advanced prostate cancer, Algeta takes aim at symptomatic bone metastases.

Sanofi's Deal With Medco/UBC Seeks Payer Perspective To Inform Drug R&D, Marketing

The multi-year, global data, research and consulting agreement will focus primarily on drugs in Phase II or III.

Beauty Of Amgen Bone Drug Results Is In Eye Of The Beholder

Top-line results from Phase III bone metastasis prevention trial lift stock price and inspire bullish headlines for Amgen. But vital figures and proof of clinical benefit are missing, making study tougher to interpret.

Related Content

Topics

UsernamePublicRestriction

Register

PS053805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel